Recce Pharmaceuticals (ASX:RCE) has announced promising new preclinical results demonstrating that its lead anti-infective, RECCE 327, delivered via inhalation, can significantly reduce bacterial burden in a validated mouse model of hospital- and ventilator-acquired pneumonia. …
Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model
November 26, 2025 Australian Biotech
Latest Video
New Stories
-
Slade Pharmacy marks anniversary with record research contributions at conferences
November 26, 2025 - - Latest News -
US Medicare sets reimbursement price for PromarkerD, paving way for major commercial rollout
November 26, 2025 - - Australian Biotech -
Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model
November 26, 2025 - - Australian Biotech -
Race Oncology secures human ethics approval for lung cancer trial of RC220
November 26, 2025 - - Australian Biotech -
Syntara advances next-generation anti-fibrotic cream into Phase 1b trial
November 26, 2025 - - Australian Biotech -
AdAlta chair says the company is 'on the cusp' of transformational growth
November 26, 2025 - - Australian Biotech -
Scorecard reveals Australia is still ignoring its deadliest and most costly cancer
November 26, 2025 - - Latest News